Literature DB >> 3902475

Total body and serum electrolyte composition in heart failure: the effects of captopril.

J G Cleland, H J Dargie, B W East, I Robertson, G P Hodsman, S G Ball, G Gillen, J I Robertson, J J Morton.   

Abstract

We compared the long-term effects of captopril and placebo on patients with heart failure in a double blind crossover fashion. Serum and total body electrolytes were measured and the response to 6 week periods of treatment with captopril determined. During the placebo phase of the study, total body potassium was low at 92 +/- 14% of predicted normal (P less than 0.05) and total body sodium was high at 104 + 7% of predicted normal (P less than 0.05). Total body chlorine did not differ from predicted normal (99 + 12%). In those patients with active plasma renin concentrations above the normal range (greater than 50 microU ml-1) total body potassium was even more markedly deplete (85 + 13% of predicted normal). This group was also characterized by lower serum potassium and sodium concentrations and lower blood pressure. Total body potassium increased significantly on captopril, and the rise was greatest in those with the highest plasma renin concentrations during the placebo phase of the study. However, captopril had no significant effect on total body sodium and chlorine or weight indicating that no long-term natriuresis had occurred.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3902475     DOI: 10.1093/oxfordjournals.eurheartj.a061920

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

Review 1.  Vascular tone in heart failure: the neuroendocrine-therapeutic interface.

Authors:  J G Cleland; C M Oakley
Journal:  Br Heart J       Date:  1991-10

2.  Mortality in heart failure: clinical variables of prognostic value.

Authors:  J G Cleland; H J Dargie; I Ford
Journal:  Br Heart J       Date:  1987-12

3.  Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension.

Authors:  J G Cleland; H J Dargie; I Robertson; J I Robertson; B W East
Journal:  Br Heart J       Date:  1987-09

4.  Volumes and Na+/H+ antiporter activity of lymphocytes in patients with congestive heart failure.

Authors:  M Christ; V Klauss; W Pliml; K Theisen; M Wehling
Journal:  Clin Investig       Date:  1994-12

5.  Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction : meta-analysis of randomised clinical trials.

Authors:  Antònia Agustí; Sara Bonet; Josep Maria Arnau; Xavier Vidal; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.

Authors:  John G F Cleland; João Pedro Ferreira; Beatrice Mariottoni; Pierpaolo Pellicori; Joe Cuthbert; Job A J Verdonschot; Johannes Petutschnigg; Fozia Z Ahmed; Franco Cosmi; Hans-Peter Brunner La Rocca; Mamas A Mamas; Andrew L Clark; Frank Edelmann; Burkert Pieske; Javed Khan; Ken McDonald; Philippe Rouet; Jan A Staessen; Blerim Mujaj; Arantxa González; Javier Diez; Mark Hazebroek; Stephane Heymans; Roberto Latini; Stéphanie Grojean; Anne Pizard; Nicolas Girerd; Patrick Rossignol; Tim J Collier; Faiez Zannad
Journal:  Eur Heart J       Date:  2021-02-11       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.